Craft
  • Home
  •  / Pharmacyclics
Pharmacyclics

Pharmacyclics

Revenue

$729.7 M

FY, 2014

Pharmacyclics Summary

Company summary

Overview
Pharmacyclics, Inc. is an integrated biopharmaceutical company engaged in developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The Company’s commercial product is IMBRUVICA (ibrutinib), which is an oral, single-agent therapy indicated for the treatment of blood cancer. IMBRUVICA (ibrutinib) is a prescription medicine used to treat people with marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment.
Type
Subsidiary
Founded
1991
HQ
Sunnyvale, CA, US | view all locations
Website
http://pharmacyclics.com
Cybersecurity rating
Sectors

Key people

  • Erik von Borcke

    Erik von Borcke, President

    • Stefan Geldmeyer

      Stefan Geldmeyer, Head of Finance and Infrastructure

      • Guowei Fang

        Guowei Fang, Head of Discovery

        • Ann Tomlin

          Ann Tomlin, Head of Human Resources

          LocationsView all

          1 location detected

          • Sunnyvale, CA HQ

            United States

            999 E Arques Ave

          Pharmacyclics Financials

          Summary financials

          Revenue (Q1, 2015)
          $205.8M
          Gross profit (Q1, 2015)
          $189.1M
          Net income (Q1, 2015)
          $4.1M
          Cash (Q1, 2015)
          $874.7M
          EBIT (Q1, 2015)
          $3.8M

          Footer menu